Nucleus Genomics
PrivateLast Round
Series A
Jan 30, 2025
Total Funding Raised
$31.5M
Company Overview
Nucleus Genomics operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A round in January 2025.
Nucleus Genomics is a biotechnology company that provides direct-to-consumer whole-genome sequencing and analysis for health risks, family planning, and preventative health.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, D2C Brands, Medical AI
Business Model
B2C
Customer Profile
Hardware Sales, Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleus Genomics Comparables
Compare Nucleus Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SelfDecode | 77% | |
| MyOme | 77% | |
| Orchid | 76% |
For institutional investors. Book with your work email.
Nucleus Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 30, 2025 | ||||
| Seed | Jul 14, 2022 | ||||
| Pre Seed | Dec 15, 2021 |
For institutional investors. Book with your work email.
Nucleus Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rose Street Capital | Series A |
| Neo | Series A |
| Founders Fund | Seed, Series A, Pre Seed |
| Asylum Ventures | Series A |
| Seven Seven Six | Seed, Series A |
| Common Metal | Series A |
| Samsung Next TLV | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 30, 2025
$14M round led by Founders Fund and Seven Seven Six.
- Jul 14, 2022
$14M round led by Seven Seven Six.
For institutional investors. Book with your work email.
Nucleus Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nucleus Genomics's valuation, stock price, and market status.
Is Nucleus Genomics a public or private company?
Nucleus Genomics is a private company.
What is the current stock price of Nucleus Genomics?
Nucleus Genomics is a private company, so its shares have no public market price. Caplight tracks Nucleus Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nucleus Genomics worth (valuation)?
Valuation information for Nucleus Genomics is not publicly available.
Can I buy Nucleus Genomics stock?
Nucleus Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nucleus Genomics's last funding round?
Nucleus Genomics's most recent funding round was Series A on January 30, 2025.
Who are the main investors in Nucleus Genomics?
Key investors in Nucleus Genomics include Founders Fund, Seven Seven Six.
Will Nucleus Genomics IPO soon?
No public IPO plans have been announced for Nucleus Genomics.
How can I track Nucleus Genomics secondary market activity?
Caplight tracks bids, offers, and trades in Nucleus Genomics's shares on secondary markets.